SARS-CoV-2 vaccine-triggered autoimmunity: Molecular mimicry and/or bystander activation of the immune system

Azam Safary1,2*, Mostafa Akbarzadeh-Khiavi1, Jaleh Barar2*, Yadollah Omidí2,3#

1Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran
3Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4Department of Pharmaceutical Sciences, Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USA

Summary

Induced autoimmunity or autoinflammatory-like conditions as a rare vaccine-related adverse event have been reported following COVID-19 vaccination. Such inadvertent adverse reactions have raised somewhat concerns about the long-term safety of the developed vaccines. Such multifactorial phenomena may be related to the cross-reactivity between the viral-specific antigens with the host self-proteins through molecular mimicry mechanism and/or nonspecific bystander activation of the non-target antigen-independent immunity by the entities of the vaccine products. However, due to the low incidence of the reported/identified individuals and insufficient evidence, autoimmunity following the COVID-19 vaccination has not been approved. Thereby, it seems that further designated studies might warrant post-monitoring of the inevitable adverse immunologic reactions in the vaccinated individuals, especially among hypersensitive cases, to address possible immunological mechanisms induced by the viral vaccines, incorporated adjuvants, and even vaccine delivery systems.

Keywords:
Autoimmunity
Bystander activation
COVID-19 vaccine
Molecular mimicry
Post-vaccination

Authors’ Biosketch

Azam Safary is an Assistant Professor of medical biotechnology at the Connective Tissue Diseases Research Center (CTDRC) and Research Center for Pharmaceutical Nanotechnology (RCPN) at Tabriz University of Medical Sciences, working on the cellular and molecular mechanisms of immune-mediated inflammatory diseases, new strategies for the detection and prevention of them, nano-formulated therapeutic enzymes, and biotechnological aspects of recombinant proteins.

Mostafa Akbarzadeh-Khiavi is an Assistant Professor of molecular medicine at the Liver and Gastrointestinal Diseases Research Center (LGDRC) and RCPN at Tabriz University of Medical Sciences, working on the development of advanced nano-formulated enzymes/antibodies used for the targeted drug delivery. Currently, he is involved in a project on cellular and molecular mechanisms of chronic disease and new strategies for diagnosing and treating them.

Professor Yadollah Omidí has a Ph.D. degree in Pharmaceutical Sciences (2003, Cardiff University, UK) and completed a postdoctoral program (2004) at Cardiff University. He is currently working as a full professor at Nova Southeastern University College of Pharmacy, Florida. Prof. Omidí’s research in advanced targeted diagnosis and therapy of diseases have resulted in over 300 published papers in international journals, 27 book chapters, and a few patents. His H-index is 61 and i10-index is 238. He has consecutively been listed among top 1% highly cited scientists worldwide by WoS-ESI.

Professor Jaleh Barar has a Ph.D. degree in Pharmaceutical Sciences (2004, Cardiff University, UK) and Pharm.D. degree from Tabriz University of Medical Sciences. She is currently working as a full professor at Barry and Judy Silverman College of Pharmacy, Nova Southeastern University (Florida, USA). Prof. Barar’s research in pharmaceutical sciences have resulted in over 200 published papers in international journals, 20 book chapters, and a few patents. Her H-index is 51 and he has consecutively been listed among top 1% highly cited scientists worldwide by WoS-ESI.

*Corresponding author: Yadollah Omidí, Email: yomidi@nova.edu

© 2023 The Author(s). This work is published by BiImpacts as an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
A more recent pandemic of COVID-19 caused by the SARS-CoV-2 is one of the most devastating global problems, seriously threatening public health worldwide.\(^1,2\) Despite the incredible effectiveness of the vaccines against COVID-19 in controlling pandemic and significantly reducing mortality, their biological impacts (e.g., long-term safety, adverse effects [AEs], and long-term efficacy) should be carefully clarified, especially among those who have chronic immune system-related disorders. The viral vaccination may be associated with mild to severe levels of AEs which are usually tolerable and harmless. However, individuals with a history of allergic reactions with possible IgE-mediated responses might severely respond to the vaccination and generate severe immunologic reactions.\(^3\)

It has been shown that viral vaccination may induce autoimmunity, as a rare vaccine-related AEs.\(^4\) Accordingly, several studies have shown autoimmune reactions after anti-infectious vaccination against tetanus, rubella, hepatitis B, and influenza.\(^5\) Following the universal vaccination of COVID-19, some concerns about vaccine-triggered autoimmunity or autoimmune-like conditions as multifactorial phenomena have been raised. Such AEs may be caused by the overstimulation of the immune system through different immunological mechanisms, including (i) antigen-specific reactions related to the epitope-based vaccines, and (ii) antigen-independent activation of CD8\(^+\)/CD4\(^+\) T or B-cells, which can be mainly addressed in the vaccines developed using conventional methods.\(^6,7\)

Molecular mimicry (MM), an antigen-specific immune response, seems to be a possible mechanism in acquired autoimmunity post-COVID-19 vaccination. Accordingly, it has been suggested that the potential cross-reactivity of the nucleoprotein/spike protein of SARS-CoV-2 with human tissue due to the viral antigenic mimicry may be connected to an increase in autoimmune diseases.\(^8\) In the occurrence of such autoimmune reactions, the cross-reaction phenomena must take place at “disease-related” epitopes. Perhaps, such phenomena might occur through peptides of self-antigens that are presented by major histocompatibility complex II (MHC class II) on antigen-presenting cells (APCs) to auto-reactive CD4\(^+\) T-cells.\(^9\) Regarding the MM hypothesis, there are concerns about using entire SARS-CoV-2 antigens in vaccine development and it seems that considering only specific and unique peptides would be the most effective strategy against such AEs.\(^10\) In addition to the MM mechanism(s), mRNA vaccines before the translation might activate several pro-inflammatory cascades and lead to aberrant responses of innate and acquired immune systems, which are the basis of numerous immune-mediated diseases. Due to the higher immune system activity against viral antigens in people under 55 years, such abnormalities may occur providing great protection against viral antigens and also making them predisposed to a higher burden of immunological AEs.\(^11\)

In addition to the specific viral antigens, the components classified as non-target antigens of a vaccine product may occasionally induce an undesired immune response in a small part of the population. Most non-target antigens can be derived from (i) the cell culture medium supplements, (ii) proteins shed from the mammalian cells into the culture medium, and (iii) adjuvants/stabilizers used for vaccine development. Bystander activation is a non-specific stimulation of auto-reactive CD8\(^+\) T cells (even CD4\(^+\)T cells/B cells), which can be initiated following antigen-specific responses against the viral vaccines. The proliferation of CD8\(^+\) T cells can be mediated by IL-15 association with its specific receptor-\(\alpha\) (IL-15R-\(\alpha\)) on the surface of the APC, which can trigger the bystander stimulation of memory-phenotype CD8\(^+\) T cells. In this pathway, the production of IL-15 can be provoked by increasing the interferons (INFs) \(\alpha/\beta\), \(\gamma\), and INF-inducer cytokines such as IL-12 and IL-18. Added to the auto-reactive CD8\(^+\) T cells, the CD4\(^+\) T cells may be stimulated through IL-2 cytokine and affected the immune responses, even though the involvement of this pathway in bystander activation is less well-known.\(^12\) It has been also suggested that vaccine adjuvants may contribute to autoimmunity by stimulating bystander activation of irrelevant T cells.\(^13\) The exact mechanism of such a process is yet to be fully clarified, for which specific studies are further needed to address such outstanding issues.

Intriguingly, it has been also proposed that autoimmunity post-vaccination may be related to specific genetic patterns, such as human leukocyte antigen in the case of multiple sclerosis following the hepatitis B vaccine.\(^14,15\) Thereby, personalized approaches such as genetic risk factors for autoimmunity must also be considered in the development of new vaccines.\(^16\) Recently, different case reports or observational studies have published autoimmune diseases post-vaccination with different types of COVID-19 vaccines (Table 1). Overall, immunological side effects may be connected to several factors such as vaccine type, vaccine dose, age, gender, specific genetic patterns, and history of immune-mediated diseases. However, the clinical trials related to the approved vaccines by the World Health Organization (WHO) did not show serious safety concerns during observation.\(^16-19\) Extensive follow-up evaluations are needed to consider long-term safety and autoimmunity issues of new vaccines for public administration.

As a perspective, some vaccinologists have recently focused on the next generation of epitope-based vaccines, which are designed based on the immunodominant/safe regions of one or more protective antigen(s).\(^34-36\) To avoid any possible undesired autoimmune reactions, amino acid residues that may show homology with vaccine recipients’ proteome are predicted. In this line, sequence-and structure-based computational methods (e.g., local alignment algorithms and molecular docking/dynamics
Simulations, respectively) are used and the possible flaws are excluded from the vaccine construct.\textsuperscript{37,38} Such an approach seems to be a time and cost-effective strategy to improve the vaccine safety in terms of potential tissue cross-reactive epitope(s).

In conclusion, autoinflammatory and autoimmune conditions may be associated with the cross-reactivity between SARS-CoV-2 viral peptides and self-antigens; thus, avoiding the stimulation of autoreactive T-cells should be considered one of the most crucial safety issues in constructing new vaccines. So far, the autoimmunity phenomenon following COVID-19 vaccination has not been approved due to the low incidence of the identified individuals and lack of sufficient evidence. Therefore, deep insight into the subject's incidental and idiopathic conditions is needed to develop this hypothesis. Moreover, further studies are warranted to monitor possible predisposed individuals and clarify immunological mechanisms induced by viral vaccines and adjuvants. Collectively, it should be emphasized that the vaccination modality is the best medical practice in controlling most infectious diseases even though autoimmunity might occur with low and mild clinical symptoms compared to those associated with the incidence of severe COVID-19 infection. Nonetheless, such symptoms could become much more severe in the cases of autoimmune diseases, in which precise care might be very helpful. Collectively, similar to other types of vaccines, SARS-CoV-2 vaccine-induced autoimmunity is a complex and dynamic area of research, characterized by molecular mimicry and immune system activation. Doubtlessly, COVID-19 vaccines have been crucial in mitigating the global impact of the pandemic. However, it is important to recognize that rare cases of autoimmune reactions might occur. These reactions may arise due to interactions between vaccine components, immune system activation, and underlying genetic predispositions. By implementing rigorous monitoring, timely reporting, and further research, we can enhance vaccine safety through quality-by-design approaches to ensure that the benefits of vaccination continue to outweigh potential risks in the battle against any emerging/re-emerging infections and future pandemics.

\textbf{Authors' Contribution}

\textbf{Conceptualization:} Azam Safary, Mostafa Akbarzadeh-Khiavi, Jaleh

### Table 1. Some autoimmune-mediated diseases following COVID-19 vaccines

<table>
<thead>
<tr>
<th>Vaccine Type*</th>
<th>Autoimmune disease</th>
<th>Age</th>
<th>Gender</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>ChAdOx1 nCoV-19</td>
<td>Immune thrombocytopenia</td>
<td>50</td>
<td>Female</td>
<td>27</td>
</tr>
<tr>
<td>mRNA-BNT162B2</td>
<td>Arthritis flare</td>
<td>55</td>
<td>Male</td>
<td>28</td>
</tr>
<tr>
<td>mRNA-1273</td>
<td>Autoimmune hepatitis</td>
<td>76</td>
<td>Female</td>
<td>21</td>
</tr>
<tr>
<td>mRNA-BNT162B2</td>
<td>Symmetric polyarthritis</td>
<td>49</td>
<td>Male</td>
<td>24</td>
</tr>
<tr>
<td>ChAdOx1 nCoV-19</td>
<td>Exacerbation of Behçet’s disease</td>
<td>28</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td>mRNABNT162B2</td>
<td>Pericarditis</td>
<td>37</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td>mRNABNT162B2</td>
<td>Temporal arteritis-like disease</td>
<td>60</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td>mRNA-BNT162B2</td>
<td>Oligoarthritis</td>
<td>37</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td>mRNA-BNT162B2</td>
<td>Myocarditis</td>
<td>22</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td>mRNA-BNT162B2</td>
<td>Guillain-Barre Syndrome</td>
<td>82</td>
<td>Female</td>
<td>25</td>
</tr>
<tr>
<td>ChAdOx1 nCoV-19</td>
<td>Graves’ disease</td>
<td>48</td>
<td>Male</td>
<td>26</td>
</tr>
<tr>
<td>mRNA-BNT162B2</td>
<td>Granulomatous vasculitis</td>
<td>77</td>
<td>Male</td>
<td>28</td>
</tr>
<tr>
<td>mRNA-BNT162B2</td>
<td>ANCA-associated vasculitis</td>
<td>78</td>
<td>Female</td>
<td>29</td>
</tr>
<tr>
<td>ChAdOx1 nCoV-19</td>
<td>Systemic lupus erythematosus</td>
<td>22</td>
<td>Female</td>
<td>31</td>
</tr>
<tr>
<td>mRNA-1273</td>
<td>Vasculitis</td>
<td>39</td>
<td>Male</td>
<td>22</td>
</tr>
<tr>
<td>BBIBP-CorV</td>
<td>Rheumatoid arthritis</td>
<td>85</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Palindromic rheumatism</td>
<td>39</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adult-onset Still’s disease</td>
<td>39</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Systemic lupus erythematosus</td>
<td>71</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Peripheral seronegative spondyloarthritis</td>
<td>61</td>
<td>Female</td>
<td>33</td>
</tr>
</tbody>
</table>

* ChAdOx1 nCoV-19, AstraZeneca; mRNA-1273, Moderna; BNT162B2, BioNTech-Pfizer; BBIBP-CorV, Sinopharm.


29. Shakoor MT, Birkenbach MP, Lynch M. ANCA-Associated


